Parvoduk

RSS

Lapsed

This medicine's authorisation has lapsed

live attenuated Muscovy duck parvovirus
MedicineVeterinaryLapsed

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

български (BG) (279.17 KB - PDF)

Vaata

español (ES) (388.86 KB - PDF)

Vaata

čeština (CS) (432.85 KB - PDF)

Vaata

dansk (DA) (386.36 KB - PDF)

Vaata

Deutsch (DE) (392.74 KB - PDF)

Vaata

eesti (ET) (372.5 KB - PDF)

Vaata

ελληνικά (EL) (456.39 KB - PDF)

Vaata

français (FR) (390.28 KB - PDF)

Vaata

hrvatski (HR) (547.54 KB - PDF)

Vaata

italiano (IT) (391.31 KB - PDF)

Vaata

latviešu (LV) (456.12 KB - PDF)

Vaata

lietuvių (LT) (421.48 KB - PDF)

Vaata

magyar (HU) (449.76 KB - PDF)

Vaata

Malti (MT) (440.69 KB - PDF)

Vaata

Nederlands (NL) (388.36 KB - PDF)

Vaata

polski (PL) (432.82 KB - PDF)

Vaata

português (PT) (389.06 KB - PDF)

Vaata

română (RO) (418.94 KB - PDF)

Vaata

slovenčina (SK) (436.71 KB - PDF)

Vaata

slovenščina (SL) (428.53 KB - PDF)

Vaata

suomi (FI) (387.48 KB - PDF)

Vaata

svenska (SV) (386.11 KB - PDF)

Vaata

Product information

български (BG) (1.19 MB - PDF)

Vaata

español (ES) (804.6 KB - PDF)

Vaata

čeština (CS) (1.03 MB - PDF)

Vaata

dansk (DA) (817.13 KB - PDF)

Vaata

Deutsch (DE) (901.86 KB - PDF)

Vaata

eesti (ET) (803.72 KB - PDF)

Vaata

ελληνικά (EL) (1.2 MB - PDF)

Vaata

français (FR) (816.73 KB - PDF)

Vaata

hrvatski (HR) (1.23 MB - PDF)

Vaata

italiano (IT) (816.1 KB - PDF)

Vaata

latviešu (LV) (1.05 MB - PDF)

Vaata

lietuvių (LT) (953.35 KB - PDF)

Vaata

magyar (HU) (997.58 KB - PDF)

Vaata

Malti (MT) (1.06 MB - PDF)

Vaata

Nederlands (NL) (808.14 KB - PDF)

Vaata

polski (PL) (1.17 MB - PDF)

Vaata

português (PT) (803.42 KB - PDF)

Vaata

română (RO) (936.44 KB - PDF)

Vaata

slovenčina (SK) (1.06 MB - PDF)

Vaata

slovenščina (SL) (1.06 MB - PDF)

Vaata

suomi (FI) (791.59 KB - PDF)

Vaata

svenska (SV) (796.96 KB - PDF)

Vaata

Íslenska (IS) (803.26 KB - PDF)

Vaata

norsk (NO) (815.13 KB - PDF)

Vaata
Latest procedure affecting product information:R/0006
09/01/2019

български (BG) (189.97 KB - PDF)

Vaata

español (ES) (281.53 KB - PDF)

Vaata

čeština (CS) (304.72 KB - PDF)

Vaata

dansk (DA) (298.36 KB - PDF)

Vaata

Deutsch (DE) (302.28 KB - PDF)

Vaata

eesti (ET) (285.5 KB - PDF)

Vaata

ελληνικά (EL) (325.92 KB - PDF)

Vaata

français (FR) (335.93 KB - PDF)

Vaata

hrvatski (HR) (307.68 KB - PDF)

Vaata

italiano (IT) (299.37 KB - PDF)

Vaata

latviešu (LV) (340.5 KB - PDF)

Vaata

lietuvių (LT) (297.31 KB - PDF)

Vaata

magyar (HU) (303.78 KB - PDF)

Vaata

Malti (MT) (306.38 KB - PDF)

Vaata

Nederlands (NL) (313.36 KB - PDF)

Vaata

polski (PL) (299.63 KB - PDF)

Vaata

português (PT) (297.7 KB - PDF)

Vaata

română (RO) (312.51 KB - PDF)

Vaata

slovenčina (SK) (304.5 KB - PDF)

Vaata

slovenščina (SL) (297.92 KB - PDF)

Vaata

suomi (FI) (295.81 KB - PDF)

Vaata

svenska (SV) (293.03 KB - PDF)

Vaata

Íslenska (IS) (292.58 KB - PDF)

Vaata

norsk (NO) (298.06 KB - PDF)

Vaata

Product details

Name of medicine
Parvoduk
Active substance
live attenuated Muscovy duck parvovirus
International non-proprietary name (INN) or common name
live attenuated Muscovy duck parvovirus
Species
Ducks
Anatomical therapeutic chemical veterinary (ATCvet) code
QI01BD03

Pharmacotherapeutic group

  • duck parvovirus
  • Live viral vaccines
  • Immunologicals for aves

Therapeutic indication

Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.


1In absence of maternally derived antibodies.

Authorisation details

EMA product number
EMEA/V/C/002740
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
11/04/2014
Lapse of marketing authorisation
01/04/2019
Revision
2

Assessment history

This page was last updated on

Share this page